Author: Matthew Ettinger
-
Oregon’s Psilocybin Centers Are Getting Safety Right. Now Comes Access.
A new independent study finds Oregon’s licensed service centers screen clients carefully and keep every session supervised. It also finds that most people who could benefit can’t afford to walk through the door. For three years, Oregon has been running the country’s first regulated psilocybin services program, and for three years supporters and skeptics alike…
-
Court Sets Date: Cusker et al. v. OHA Heads to Oral Argument on November 16
The National Psychedelics Association announced a pivotal court hearing on November 16, 2026, addressing psilocybin accessibility for disabled and terminally ill Oregonians, crucial for shaping future service programs.
-
We did it. Now let’s keep pushing.
In September, the FDA held a public hearing on Psychedelic Drug Therapy, with 80 speakers highlighting the need for representation. Oregon’s Health Authority reversed planned fee increases for Psilocybin Services after widespread community advocacy. The importance of collective action was emphasized, encouraging facilitators to join forces and participate actively to influence future changes.
-
Oregon OHA Drops Psilocybin Fee Increases
September 22, 2026 This morning, the Oregon Health Authority made it official: the proposed psilocybin rule-making that would have sharply increased licensing fees is dead. OHA will not be moving forward with the rules identified in its August 28, 2026 Notice of Proposed Rulemaking, which means the fee increases at the heart of that package…
-
Public Testimony Against Rising Psilocybin Fees in Oregon
At a public hearing, stakeholders expressed overwhelming opposition to proposed fee increases for Oregon’s psilocybin services program, arguing that these would worsen budget shortfalls and reduce access. Testimonies highlighted concerns about the financial viability for facilitators and the risk of driving them out of the regulated market, potentially harming clients who rely on these services.
-
Key Insights from FDA’s Psychedelic Drug Hearing
On September 14, 2026, the FDA hosted a public hearing on psychedelic drug therapy considerations, attracting 80 speakers who debated training, safety, access, and data standards. Consensus emerged on the need for interdisciplinary care and robust safety measures post-treatment. The hearing emphasized that effective psychedelic care relies on integrated systems rather than isolated approaches.
-
Why the Psychedelic-Assisted Care Field Needs an Association — And Why We Hope It’s Us
If you’re reading this, you already know something the rest of the world is just catching up on: this work is powerful, it’s hard, and it’s lonely in ways that surprise even the most prepared practitioner. You went through training, built a practice or joined a service center, and somewhere along the way realized no…
-
FDA – Public Comments
Dear NPA Community, This is a pivotal moment. The FDA has announced a public hearing on the future of psychedelic therapy, and they are actively seeking input from patients, practitioners, advocates, and the broader community. On September 14, 2026, the FDA will hold its Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing.…
-
100+ Joined Our Virtual Community Session Recently, Where we Shared Critical Infrastructure Advancements
On December 16th, the National Psychedelics Association (the NPA) convened a well-attended virtual briefing over Zoom, bringing together facilitators, service center operators, training providers, and allied professionals from across Oregon, Colorado, and even beyond. The session was structured as a working update rather than a formal presentation, walking the community through six big benefits we offer, including…
-
Urgent Action on Psilocybin Petition
RE: Psilocybin Rescheduling Petition, Dr. Sunil Aggarwal, AIMS Institute Dear Assistant Administrator Prevoznik: This is in further follow up to your letter to Dr. Sunil Aggarwal of the AIMS Institute, dated February 3, 2025, addressing our February 2, 2022 petition to transfer psilocybin from schedule I to schedule II of the Controlled Substances Act. Pursuant…